Wedbush Reiterates Neutral Rating for REGENXBIO (NASDAQ:RGNX)

REGENXBIO (NASDAQ:RGNX – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at Wedbush in a research report issued on Wednesday, RTT News reports. They presently have a $21.00 target price on the biotechnology company’s stock. Wedbush’s price objective indicates a potential upside of 47.27% from the company’s previous close. Several other research […]

Related Keywords

Canada ,Stifel Nicolaus ,William Blair ,Steve Pakola ,Commonwealth Of Pennsylvania Public School Empls Retrmt ,Securities Exchange Commission ,Company Profile ,Mitsubishi Ufj ,Sigma Planning Corp ,York Mellon Corp ,Kokusai Asset Management Co ,Royal Bank ,Jennison Associates ,Technology Platform ,Get Free Report ,Exchange Commission ,Planning Corp ,New York Mellon Corp ,Pennsylvania Public School Empls Retrmt ,Asset Management ,Regenxbio ,Nasdaq Rgnx ,Rgnx ,Medical ,Reiterated Rating ,Wedbush ,